1/34
Comprehensive vocabulary flashcards covering obstetric tocolytics, labor inducers, hormonal contraceptives, ophthalmic antiglaucoma agents, and otic medications from NCM 106 Module 9F.
Iron Products (PO Dosing in Pregnancy)
Oral iron supplements (such as ferrous sulfate, ferrous gluconate, and ferrous fumarate) indicated at a dose of 15mg once daily in the first trimester, and 27mg once daily during the last two trimesters to prevent and treat iron deficiency anemia.
Liquid Iron Administration
A formulation that causes discoloration of teeth; interventions include diluting the liquid, having the client drink it with a straw, and administering it on an empty stomach with water, juice, or Vitamin C to enhance absorption.
Folic Acid (Vitamin B9)
A water-soluble B vitamin whose deficiency early in pregnancy can cause spontaneous abortion, premature birth, low birth weight, placental abruption, and neural tube defects (NTDs); clients with a prior pregnancy affected by an NTD require a higher prophylactic dose of 4000mcg starting 1 to 3 months prior to conception.
Preterm Labor (PTL)
The occurrence of cervical changes and regular uterine contractions occurring between 20 and 37 weeks of gestation, representing the leading cause of newborn and infant mortality.
Tocolytics
Off-label medications that interrupt or inhibit uterine contractions to buy time for fetal maturation, allow antenatal corticosteroid administration, and permit maternal transport to an appropriate care facility.
Terbutaline
A beta-sympathomimetic tocolytic bearing a Black Box Warning against prolonged use or prevention of PTL; adverse maternal effects include tachycardia, tremors, hyperglycemia, and hypokalemia; contraindicated in cardiac disease, poorly controlled hyperthyroidism, and diabetes mellitus.
Magnesium Sulfate (Tocolytic)
A calcium antagonist and central nervous system depressant that relaxes uterine smooth muscle through calcium displacement, given as an off-label tocolytic with a 4 to 6g IV loading dose over 20 to 30minutes, followed by 1 to 2g/h for up to 48hours.
Magnesium Toxicity Danger Signs
Clinical warning signs during magnesium sulfate therapy comprising loss of deep tendon reflexes (DTRs), maternal confusion, decreased fetal heart rate (FHR), and neonatal respiratory depression or hypotonia.
Calcium Gluconate
The specific antidote for magnesium sulfate toxicity, administered at a dose of 1g IV over 3minutes.
Therapeutic Serum Magnesium Level
The target serum concentration during magnesium sulfate tocolytic therapy, defined as 4 to 7mg/dL.
Dinoprostone Cervical Gel
A naturally occurring prostaglandin containing 0.5mg dinoprostone in 2.5mL used intracervically to ripen an unfavorable cervix; requires recumbency for 15 to 30minutes after administration and a waiting period of 6 to 12hours before initiating oxytocin.
Oxytocin
A uterine stimulant used for labor induction, augmentation, and control of postpartum hemorrhage; prepared by diluting 10units in 1000mL lactated Ringer's (10milliunits/mL) and administered as a secondary IV piggyback to prevent tachysystole and water intoxication.
Methylergonovine Maleate
An ergot alkaloid that stimulates smooth muscle to produce tetanic contractions, used exclusively after delivery to control postpartum hemorrhage and promote involution; contraindicated in gestational hypertension and peripheral vascular disease.
Ergotism
Toxicity caused by ergot alkaloids characterized by numbness, cold extremities, severe limb and lower back pain, muscular weakness, seizures, hallucinations, and blood hypercoagulability resulting from intense vasoconstriction.
Combined Hormonal Contraceptives (CHCs)
Contraceptive formulations combining synthetic estrogen (which inhibits ovulation) and progestin (which suppresses the LH surge and thickens cervical mucus) to produce drug-induced anovulatory cycles.
Withdrawal Bleeding
Scheduled monthly bleeding (pseudomenstruation) occurring during the hormone-free interval of combined hormonal contraceptive therapy, mimicking a regular 28-day menstrual period.
Breakthrough Bleeding
Unscheduled or unexpected bleeding or spotting occurring while actively taking hormonal contraceptive medications.
Missed CHC Protocol (1 Tablet)
Take the missed tablet as soon as remembered and take the next tablet at the regularly scheduled time without requiring backup contraception.
Missed CHC Protocol (2 Tablets)
Take 2 tablets as soon as remembered and 2 tablets the following day, accompanied by a back-up contraceptive method for the remainder of the cycle.
Missed CHC Protocol (3 Tablets)
Discontinue the pack to permit withdrawal bleeding, begin a new pack 7days after the last tablet was taken, and use an additional contraceptive method until new tablets have been taken for 7 consecutive days.
Transdermal Contraceptive Patch
A weekly combined hormonal system delivering ethinyl estradiol (20mcg or 35mcg) and norelgestromin (150mcg) every 24hours, applied for 3 consecutive weeks followed by 1 patch-free week; ineffective in women weighing 198lbs or more.
Transvaginal Contraceptive Ring
A flexible, colorless indwelling ring releasing 15mcg ethinyl estradiol and 120mcg etonogestrel daily; retained for 3weeks and removed for 1week; requires backup contraception for 7days if expelled for greater than 3hours.
Progestin-Only Pills (POPs)
Oral contraceptives containing 0.35mg norethindrone taken continuously every single day within a strict 3-hour window; a delayed dose requires back-up contraception for 48hours.
Depot Medroxyprogesterone Acetate (DMPA)
A long-acting injectable progestin administered at 150mg/mL deep intramuscularly into the ventral gluteus or deltoid every 11 to 13weeks; injection site must not be massaged.
Etonogestrel Subdermal Implant
A single, radiopaque rod containing 68mg etonogestrel placed in the inner upper non-dominant arm providing contraception for up to 3years.
Prostaglandin Analogues (Ophthalmic)
First-line antiglaucoma agents (e.g., latanoprost, bimatoprost, travoprost, tafluprost) administered at bedtime that reduce intraocular pressure by improving uveoscleral and trabecular outflow; can cause irreversible brown iris pigmentation and hypertrichosis of eyelashes.
Timolol (Ophthalmic)
A nonselective beta-adrenergic blocker that decreases aqueous humor production without altering pupil size; contraindicated in patients with asthma, chronic obstructive pulmonary disease (COPD), bradycardia, heart failure, and advanced AV block.
Alpha-Adrenergic Agonists (Ophthalmic)
Sympathomimetic agents (such as apraclonidine and brimonidine) that act on the ciliary body to decrease aqueous humor production and increase outflow; contraindicated concurrently with monoamine oxidase inhibitor (MAOI) therapy.
Carbonic Anhydrase Inhibitors (CAIs)
Sulfonamide-derived medications (topical dorzolamide, brinzolamide; systemic acetazolamide) that decrease aqueous humor formation; contraindicated in individuals with sulfonamide allergies and capable of inducing hyperuricemia or gout.
Mydriatics and Cycloplegics
Diagnostic ophthalmic agents where mydriatics dilate pupils and cycloplegics paralyze accommodation; both are strictly contraindicated in angle-closure glaucoma due to the risk of precipitating an acute rise in intraocular pressure.
Dapiprazole
An ophthalmic alpha-adrenergic receptor antagonist utilized specifically to reverse diagnostic mydriasis induced by phenylephrine.
Ophthalmic Administration Interval Rule
The nursing standard requiring eyedrops to be instilled prior to eye ointments, with a mandatory waiting period of at least 5minutes between the administration of different ophthalmic medications.
Acute Otitis Media (AOM)
An infection of the middle ear most commonly seen in children under 2years of age, characterized by otalgia, a bulging tympanic membrane, and eustachian tube dysfunction; treated first-line with high-dose amoxicillin (80 to 90mg/kg).
Otitis Externa (OE)
An infection of the external auditory canal commonly termed swimmer's ear, predominantly caused by Pseudomonas aeruginosa or Staphylococcus aureus, treated with topical fluoroquinolones such as ciprofloxacin otic 0.2% or ofloxacin otic 0.3%.
Cerumenolytics
Topical otic formulations used to soften or remove earwax; categorized into water-based agents that hydrate and disintegrate dried cerumen, and oil-based preparations that lubricate and soften without disintegration.